Navigation Links
Pacira Pharmaceuticals, Inc. Announces Pricing of Follow-On Offering
Date:11/16/2011

PARSIPPANY, N.J., Nov. 16, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced the pricing of its public offering of 7,000,000 shares of its common stock at a price of $6.50 per share. All of the 7,000,000 shares are newly issued and are being offered by Pacira, with expected net proceeds to Pacira of approximately $42.3 million after deducting underwriting discounts and commissions and estimated offering expenses. In addition, Pacira has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares to cover over-allotments, if any.

Barclays Capital Inc. and Jefferies & Company, Inc. are acting as joint book-running managers for the offering. Piper Jaffray & Co., Wedbush PacGrow Life Sciences and Brean Murray, Carret & Co. are acting as co-managers for the offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. A copy of the final prospectus for this offering may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, at 1155 Long Island Avenue, Edgewood, NY 11717, or by calling 1-888-603-5847 or by emailing Barclaysprospectus@broadridge.com. A copy of the final prospectus may also be obtained from Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, telephone: (877) 547-6340, email
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
3. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
4. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
5. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
6. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
7. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
8. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
9. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
10. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
11. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... DALLAS , July 1, 2015 ... Reagents and Equipment Market by Method (Biochemical (Calcium Phosphate, ... Protein Production) - Analysis & Global Forecast to 2020", ... is expected to reach around $957.9 Million by 2020 ... Browse 116 market T ables ...
(Date:7/1/2015)... -- Celsion Corporation (NASDAQ: CLSN ), an oncology drug ... , Chairman, President and CEO, is scheduled to present ... July 8, 2015, at 4:15 p.m. Eastern Time. The conference ... at 119 W. 56th Street, New York ... the presentation will be available in the Events & ...
(Date:7/1/2015)... Radiant Insights announce that it ... Market Shares, Strategy, and Forecasts, Worldwide, 2015 to ... as the aging population worldwide needs homecare oxygen treatment. ... oxygen is able to improve the quality of the ... affordable and support a mobile lifestyle even while on ...
Breaking Medicine Technology:Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 2Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 4Celsion Corporation to Present at Cantor Fitzgerald's Inaugural Healthcare Conference on July 8, 2015 2Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 2Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 3Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 4
... Than for Asthma,Rheumatoid Arthritis and Migraines, WAYNE, Pa., ... of,four ulcerative colitis (UC) sufferers (73 percent) responding ... has become a normal part,of life. Furthermore, they ... relationship with a spouse (64 percent), their sexual,relations ...
... - Results,published this week in The Lancet show ... (Types 6, 11,16, 18) Recombinant Vaccine) was 100 ... caused by HPV,types 16 and 18, two types ... was observed in women who were not,infected with ...
Cached Medicine Technology:Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 2Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 3Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 4Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 5Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 6Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 7Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 8Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 9Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 2Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 3Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 4Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 5Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 6Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 7Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 8Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 9Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 10Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 11Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 12Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 13Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 14Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 15Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 16Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 17Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 18Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 19Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 20Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 21Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 22Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 23Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 24Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 25Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 26Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 27Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 28
(Date:7/1/2015)... ... July 01, 2015 , ... As if mood swings, cramps and child ... number of women: leg pain. Northeast Houston Vein Center is offering tips on the ... venous reflux disease, is underdiagnosed and often overlooked. Many women experience the tiredness, achiness, ...
(Date:7/1/2015)... ... July 01, 2015 , ... RowdMap Inc. is ... released white paper: “Pro-actively Identifying the High-Cost Patient Population: Insights from the Health ... available at: http://www.hcttf.org/resouces-tools . , The Healthcare Transformation Task Force is a ...
(Date:7/1/2015)... ... 2015 , ... Boar’s Head Brand®, one of the nation’s ... Day celebrations with new takes on classic dishes. From chicken salad with a ... summertime get together. , “Celebrating with family, friends, and great food is an ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Author Francesca Camp wasn’t always ... into her lap, so too did her support of the practice; a terrible car accident ... In her new book, “Do I Need It ? (And What if I Do?): ...
(Date:7/1/2015)... ... July 01, 2015 , ... Who doesn’t want a life ... life with a healthy balance between work and life, and positive friendships and relationships? ... book, Positive Health: Flourishing Lives, Wellbeing in Doctors. , With a focus on solving ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 2Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 3Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 3Health News:Boar’s Head Helps Craft a Delicious Independence Day 2Health News:Boar’s Head Helps Craft a Delicious Independence Day 3Health News:Francesca Camp’s New Book Unmasks Plastic Surgery Advice 2Health News:Medical Doctor Explains The Healthy Effects of a Positive Outlook in New Book 2
... , , , ... Medical Services,Holdings Limited (NYSE: CCM ) ("CMS" or ... imaging centers in China in terms of,revenues and the total ... initial public offering of 12,000,000 American Depositary Shares,("ADSs"), each representing ...
... , RICHMOND, Va., Dec. ... 2009 Industry Report: Virginia Hospitals and Nursing Facilities ... facilities and other health care providers. The report contains ... on providers, costs, profits and charity care. , The ...
... Dec. 11 UPMC Health Plan announced today that it has ... Science®, at no cost, to all UPMC for Life ... of the UPMC Health Plan wellness services, which focus on both ... the Insight(TM) Brain Fitness Program , is a suite of ...
... , SPRINGFIELD, Mass., Dec. 11 ... Council of America (WELCOA) Gold Well Workplace Award for its commitment ... Well Workplace Award, created by the Wellness Councils of America, is ... their worksite health promotion. MassMutual is one of only 60 ...
... on cardiovascular risk factors and treatment effects are ... patients are most likely to benefit from close ... findings published in the December 15/22, 2009, Prevention ... of the American College of Cardiology aim ...
... This release is available in German . ... of an apartment block and is located on the site of ... of the earth are kept out here as effective as nowhere ... of, e.g., the human heart. This was the motivation for ...
Cached Medicine News:Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 2Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 3Health News:VHI Releases Annual Industry Report - Highlights Hospital, Nursing Facility Efficiency 2Health News:UPMC Health Plan Offers Brain Fitness Software to Improve Health 2Health News:UPMC Health Plan Offers Brain Fitness Software to Improve Health 3Health News:MassMutual Recognized as One of America's Healthiest Companies 2Health News:MassMutual Recognized as One of America's Healthiest Companies 3Health News:New research identifies modifiable risk factors for heart disease 2Health News:New research identifies modifiable risk factors for heart disease 3Health News:New research identifies modifiable risk factors for heart disease 4Health News:New research identifies modifiable risk factors for heart disease 5Health News:New research identifies modifiable risk factors for heart disease 6Health News:Magnetic field measurements of the human heart at room temperature 2Health News:Magnetic field measurements of the human heart at room temperature 3
... Simplex™ P with Tobramycin ... Bone Cement formula, with the ... By maintaining the original formula, ... performance characteristics of Simplex™ P ...
... Flow Analyzer is a fast, clinically proven ... of low and normal-tension glaucoma., ,The Ocular ... clinically proven measurement that improves detection of ... management of glaucoma, and detection of other ...
... Flexible Dosposable Easy Insertion/Removal ... (CSS) provides absolutely reliable support to ... thereby permitting routine phacoemulsification regardless of ... easy (similar to disposable iris retractors), ...
The collagen intracanicular plugs have a smooth proprietary finish that simplifies insertion of the plug. Collagen plugs are ideal for short term, diagnostic and post-surgical occlusion. Plugs are 2m...
Medicine Products: